Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellCept in Lupus Nephritis
NCT02081183Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate mofetil in lupus nephritis (LN) (2 arms), sponsored by Roche. Primary endpoints: Creatinine Clearance at 18 months, Urinary Protein at 18 months and 2 more. Started Mar 2006; status: terminated.
02
Drugs
mycophenolate mofetil
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT02081183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081183.